June 19, 2018 6:14 PM ET

Pharmaceuticals

Company Overview of Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Company Overview

Staidson (Beijing) Biopharmaceuticals Co., Ltd. engages in the research, development, production, and marketing of biological products in China. Its products include Su peptide, an injection of mouse nerve growth factor; Shu Taiqing, a polyethylene glycol powder for bowel and constipation indications; Shu Wei Yan, a trospium chloride capsule for the treatment of overactive bladder; and aspirin enteric-coated tablets, glicre tablets, naproxen capsules, and other products. The company was founded in 2002 and is based in Beijing, China.

Beijing Economic and Technological Development Zone

No. 36, Jinghai Er Road

Beijing,  100176

China

Founded in 2002

Phone:

86 10 6751 9888

Fax:

86 10 6751 9794

Key Executives for Staidson (Beijing) BioPharmaceuticals Co., Ltd.

Staidson (Beijing) BioPharmaceuticals Co., Ltd. does not have any Key Executives recorded.

Staidson (Beijing) BioPharmaceuticals Co., Ltd. Key Developments

Staidson (Beijing) Biopharmaceuticals Co., Ltd., 2017 Earnings Call, Mar 02, 2018

Staidson (Beijing) Biopharmaceuticals Co., Ltd., 2017 Earnings Call, Mar 02, 2018

Staidson (Beijing) Biopharmaceuticals Co., Ltd. Proposes Amendments to the Company's Articles of Association

Staidson (Beijing) Biopharmaceuticals Co., Ltd. announced that at the annual general meeting to be held on 09 March 2018, the company proposed amendments to the company's articles of association.

Staidson (Beijing) Biopharmaceuticals Co., Ltd., Annual General Meeting, Mar 09, 2018

Staidson (Beijing) Biopharmaceuticals Co., Ltd., Annual General Meeting, Mar 09, 2018, at 10:00 China Standard Time. Agenda: To consider the 2017 work report of the board of directors; to consider the 2017 work report of the supervisory committee; to consider the 2017 annual accounts; to consider the 2017 annual report and its summary; to consider the 2017 profit distribution plan; to consider the reappointment of audit firm; to consider the 2018 remuneration plan for directors and supervisors; to consider the repurchase and cancellation of some locked restricted shares granted to plan participants; to consider the changed of the registered capital of the company; and to consider the amendments to the company's articles of association.

Recent Private Companies Transactions

Type
Date
Target
Private Placement
June 11, 2018
Staidson BioPharma Inc.
Merger/Acquisition
August 22, 2017
Beijing Defengrui Biotechnology Co., Ltd.
Private Placement
June 26, 2017
Staidson Hong Kong Investment Company Limited
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Staidson (Beijing) BioPharmaceuticals Co., Ltd., please visit www.staidson.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.